The promising results have formed the basis for initiating phase I clinical trials to evaluate the safety, efficacy and maximum tolerated dose of anti-CEA CAR-T cell therapy in CEA-positive cancers, including NSCLC (NCT02349724, NCT04348643) and advanced lung cancer (NCT06768151, NCT06043466). The gene discussed is CEACAM5; the disease is lung cancer.